Ras pathway–activated tumor cell

Ras pathway–activated tumor cells is not a specific molecular target but rather refers to **tumor cells in which the Ras signaling pathway is constitutively activated**, typically due to oncogenic mutations in one of the RAS genes (such as KRAS, NRAS, or HRAS). These mutations lead to persistent activation of downstream effectors including Raf kinases (notably Raf-1), MEK, ERK/MAPK pathways, and small GTPases like Rac and Rho. This results in increased cellular proliferation, survival, cytoskeletal changes associated with invasion and metastasis, and resistance to apoptosis[1]. While these cells are a focus for therapeutic intervention—often by targeting components of the Ras signaling cascade—they do not represent a single protein or receptor but rather a class of cancer cells defined by their aberrant signal transduction profile. Therefore, "Ras pathway–activated tumor cell" should not be considered a canonical molecular target; instead, individual proteins within the pathway (e.g., KRAS protein or Raf kinase) are valid targets[1].

Other names

Ras-activated cancer cellRas-driven tumor cellOncogenic Ras-transformed cell